COVID-19 is presenting huge challenges for all of us. I hope that you and your families are keeping safe and staying well, and if you are unwell, we wish you a speedy and full recovery.
As a valued supporter of our research, it’s important that we keep you informed of what we are doing during the crisis.
Several of our senior scientists are now contributing to the enormous COVID-19 global research effort and we have readily lent equipment to meet both research and clinical needs. All of our clinically-qualified researchers are now fully dedicated to clinical work on the front line, both at our partner hospital The Royal Marsden and elsewhere. I hope you will join me in expressing your huge admiration for them all.
Sadly, cancer won’t be self-isolating during this time, so the need for our work continues to grow, even though most of our laboratories have now closed for a period. As you will have seen and heard in the media, many cancer patients are more vulnerable than ever at times like these, and this adds even greater urgency to our need to understand cancer better and to design smarter, kinder and more effective treatments.
Thankfully, we are able to continue with our computational, data-driven research and this means for instance, that some of our work at the forefront of combating cancer evolution and drug resistance is progressing. And when the crisis is over, I can assure you that we will kickstart our laboratory-based research with even greater resolve and dedication.
We are in no doubt that the ICR’s income will be hit in the short term. Many of you know already that fundraising events everywhere have been cancelled; some people will have less money for charitable giving; and we are already experiencing some cuts to research funding.
Some of you are continuing to give and to raise funds and I’m extremely grateful to you for helping us at this most difficult of times when we still have research ongoing and costs to meet. To those of you who are not able to do so, I understand, and can only say that when the crisis is over and we re-open all of our laboratories, we will need you just as much then, to help us compensate for lost research hours in making the discoveries that defeat cancer.
We will endeavour to keep you informed of developments here at the ICR over the coming weeks and months – and until next time, I’d just like to say thank you and stay safe.
With warmest wishes,
Professor Paul Workman, CEO